FOXO News & Events

FOXO Technologies announces the closing of the acquisition of Vector Biosource. Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 and is expected to grow significantly post-acquisition. The purchase price consists of: $500,000 in cash, 60,000 shares of the Company's Series E Cumulative Redeemable Secured Preferred Stock, warrants to purchase $2 million of the Company's common stock at a 10% premium to the common stock's closing price one day prior to closing, and up to an additional 80,000 shares of Series E Preferred Stock subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. In addition, FOXO has agreed to fund up to $1.2 million of Vector's growth initiatives.

FOXO Technologies signed a stock purchase agreement to acquire Vector Biosource. Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 and is expected to grow significantly post-acquisition. The expected purchase price consists of: $500,000 in cash, 60,000 shares of the Company's Series E Cumulative Redeemable Secured Preferred Stock, warrants to purchase $2M of the Company's common stock at a 10% premium to the common stock's closing price one day prior to closing, and up to an additional 80,000 shares of Series E Preferred Stock subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO has agreed to fund up to $1.2M of Vector's growth initiatives.

FOXO Technologie received a letter from NYSE on August 12, 2025 confirming that NYSE Regulation has determined to commence proceedings to delist the Class A common stock of FOXO from NYSE American, pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the Class A commons stock. The share price went below the NYSE minimum price of $0.10 on August 12, 2025 and was immediately suspended from trading by NYSE. The Company submitted an application to have its common stock traded on the OTC and has on August 12, 2025 received confirmation from FINRA's Department of Market Operations that the trading symbol, "FOXO" has been assigned by them to the Common Stock of Foxo Technologies, Inc., and that the Company's Common Stock may be quoted and traded on the OTC market as of August 13, 2025.

FOXO Technologies announces that it has executed a non-binding acquisition agreement to acquire an assisted living and memory care facility in South Florida. The proposed acquisition includes the land and buildings. The facility has 87 units licensed for the provision of assisted living and memory care services. The purchase price for the facility is expected to be $22 million, a portion of which is milestone-based. $5M of the purchase price will be in the form of non-convertible preferred stock. Completion of the acquisition is subject to definitive agreements and a number of closing conditions, including satisfactory due diligence and financing.